Osimertinib In EGFR Mutant Lung Cancer

NCT03586453 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Carcinoma, Non-Small-Cell Lung

Interventions

DRUG: Osimertinib

Sponsor

Dana-Farber Cancer Institute

Collaborators

AstraZeneca